English
Regional settings| Spread | 0.9 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ CHF 5,000.00 Short position overnight fee ~ CHF 4,000.00 | -0.014959% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ CHF 5,000.00 Short position overnight fee ~ CHF 4,000.00 | -0.007263% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | CHF | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Switzerland | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 218.8 |
| Open | 219.9 |
| 1-Year Change | -22.05% |
| Day's Range | 218.9 - 220.9 |
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
BRIEF: For the fiscal year ended 31 December 2021, Roche Holding AG revenues increased 8% to SF62.8B. Net income decreased 3% to SF13.93B. Revenues reflect Diagnostics segment increase of 29% to SF17.76B, Chugai segment increase of 20% to SF4.51B, Rest of Europe segment increase of 16% to SF11.38B, Rest of Asia segment increase of 13% to SF9.75B, Germany segment increase of 29% to SF4.29B.
3 April 2001, 100 for 1 stock split.
